Search Results
Dr. John Kuruvilla invites you to the CARE Congress on Biosimilars on April 6th!
CCH-QC Montréal 2017: Dr. John Kuruvilla - Hodgkin's Lymphoma
John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL
CCH-QC Montréal 2017: Dr. John Kuruvilla - Early Treatment in Follicular Lymphoma
CHC 2020 is now DIGITAL: Join us on October 1-3
John Kuruvilla | EHA 18 | SADAL clinical trial in DLBCL
CARE Update in Hodgkin's Lymphoma by Dr. John Kuruvilla (Princess Margaret Cancer Centre)
T Cell Engager Antibodies – focus on Hematological Malignancies | Presented by Dr. John Kuruvilla
Dr. Kuruvilla on the Broad Utility of Pembrolizumab in Hodgkin Lymphoma
Randomized, Phase 3, Keynote-204 Study
Phase III KEYNOTE-204: does prior therapy impact outcomes in R/R cHL?
What are the challenges of integrating therapy around autologous transplantation?
